Navigation Links
Ardea Biosciences to Present at Upcoming Investor Conferences
Date:6/1/2011

SAN DIEGO, June 1, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences:

  • Jefferies 2011 Global Healthcare Conference in New York, NY. Presentation: 10:00 a.m. EDT on Monday, June 6, 2011.
  • Wells Fargo Securities Healthcare Conference in Boston, MA. Presentation: 8:30 a.m. EDT on Wednesday, June 22, 2011.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 (RDEA119) is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
10. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
11. Ardea Biosciences Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart ... 2014 was a record-breaking year across the board for the ... Smart Data Platform and our Smart Data solutions, our customers ... data which led to record growth for the company in ...
(Date:1/22/2015)... Rootstown, OH (PRWEB) January 22, 2015 Crystal ... announced today that it has received AOAC-PTM Certifications for the ... O111, O121, and O145; collectively referred to as STEC or ... at 1 colony forming unit (cfu) per 325 g of ...
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... Julio E Celis 1 , Morten stergaard 1 , Pamela Celis 1 , Hanne Holm Rasmussen ... , 1 Department of Medical Biochemistry and Danish ... Aarhus, Aarhus, Denmark , 2 Department of Urology, ... Bladder cancer comprises a broad spectrum of tumors that includes transitional , ...
... Aiguo Zhang, Allora Aguilera, Chate Luu, Ivan Huang,Diana Davis, Chloe Etienne, Yong Song, Reni Thomas,Kris Simonyi, Jim Wong, Quan Nguyen ... Science Group, 2000 Alfred Nobel Drive, , Hercules, CA 94547 , ... The American Society for Cell Biology , December 9-13, 2000 , ... , , , ...
... Data submitted by Dr. Ivan Kaiser, University of Wyoming,Laramie, WY USA , ... , Dr. Ivan Kaisers research involves ... snake venom, such as post-synaptic neurotoxins and hemorrhagic , ... purification, in which students study the principles of protein ...
Cached Biology Technology:Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 2Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 3Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 4Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 5Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 6Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 7Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 9Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 10Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 11
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... be effective in treating kidney disease, report scientists at the ... the online edition of the Proceedings of the National Academies ... drug is rapamycin, also called sirolimus, and is currently used ... new, transplanted kidney. , Over 600,000 people in the ...
... lure of chocolate or the bitter taste of strychnine would ... as to be hard-wired into the brain. Indeed, in studies ... colleagues reported in the January 19, 2006, issue of Neuron ... they said, favor a model for taste encoding in the ...
... is developing a novel gene therapy aimed at selectively ... development of Parkinson's disease. , The gene therapy, described ... Neurology, was designed by Martha Bohn and her laboratory ... , Bohn is Medical Research Council Professor and director ...
Cached Biology News:Scientists discover that widely available drug also helps fight kidney disease 2Scientists discover that widely available drug also helps fight kidney disease 3How taste response is hard-wired into the brain 2Gene therapy 'turns off' mutation linked to Parkinson's disease 2
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... Product Goat polyclonal to Cholesterol Oxidase ... Reactivity / Specificity Cross-reacts with bacteria. ... Background Information Cholesterol oxidases exist as ... and are implicated in bacterial pathogenesis. In ...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Biology Products: